Visbion awarded government grant from Innovate UK SMART initiative for Synthetic Biology project
- Posted on 18 September, 2015
Visbion are delighted to have been chosen as the recipient of a government grant via the Innovate UK SMART initiative for a new project entering into the field of synthetic biology. The aim of the project, entitled ‘A Comprehensive Web-based Broker for Biotechnology Design and Manufacturing’ is to create a method by which synthetic biology designers can efficiently search for tools and component parts for their designs.
This will be achieved by utilising Visbion’s existing DICOM systems to develop a web-based broker system. The SMART initiative aims to provide funding for research and design projects in the fields of science, engineering and technology to develop products and services which might promote economic growth.
Visbion are already members of SynbiCITE and are fortunate to have in their chairman Professor Richard Kitney and their CEO Dr Stefan Claesen, experts in the fields of synthetic biology and DICOM technology who can lead the team through the project. The remainder of the team will consist of Visbion staff members alongside specialists from Imperial College’s Centre for Synthetic Biology and Innovation (CSynBI). The project has a timescale of approximately 2 years and the initial stages of this fascinating new venture are already well underway. The team are excited to see where work will take them over the coming months.
Visbion specialises in medical image management and display solutions. The company has extensive experience in interfacing medical imaging equipment from a large variety of vendors and provides software and hardware solutions for the acquisition, storage, archive and display of a wide range of medical images.
Visbion has developed specific products for the Healthcare, Veterinary and Life Sciences markets, based on a common technology platform that provides a proven, highly-scalable and high functionality basis for the Visbion product set. In addition, the company’s technology is embedded as the image management system within a number of leading electronic medical record systems and practice management systems provided by other vendors around the world.
About CSynBI and SynbiCITE
The Centre for Synthetic Biology and Innovation (CSynBI) was established in 2009 as a centre for research, development and training in the area of synthetic biology. It is comprised of scientific researchers from Imperial College, London and societal and ethical researchers from King’s College, London, ensuring that all research is performed in a responsible way. Alongside the research, CSynBI offer teaching as part of a variety of undergraduate and postgraduate courses.
Synthetic Biology Innovation, Commercial and Industrial Translation Engine (SynbiCITE) are a collection of academic and industrial organisations focused on the commercialisation of synthetic biology. They aim to be the link between academic research of synthetic biology and its practical application within industry.
Share this article:
People also read
Evonetix raises $30 million USD (£23 million GBP)
Series B investment led by west-coast investor Foresite Capital, with all existing investors participating in the roundFunds will be used to accelerat...
Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform
CAMBRIDGE, UK, and LEUVEN, Belgium, 13 January 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scala...
Biotech firm MiAlgae secures £1m to turn whisky by-products into pet and fish food
An Edinburgh-based biotech startup which turns whisky distillation by-products into pet and fish food has received investment of £1 million.MiAlgae pr...